Key result
EIP-22 limits myocardial ischemia-reperfusion injury and improves cardiac function in mice via JAK2/STAT3 activation.
Why the study?
Primary PCI has become the reperfusion treatment of choice for acute STEMI with increased use and advances in adjunctive therapies, but challenges remain for practitioners.
p-value: p=<.05
Hypothesis-generating in murine models; human trials needed before any clinical consideration in reperfusion injury.
Primary percutaneous coronary intervention (PPCI) is the reperfusion treatment of choice for acute ST-elevation myocardial infarction with studies having demonstrated improved outcomes with PPCI over thrombolysis. Its use has increased substantially over the last decade, overtaking thrombolytic therapy in many countries. This has been paralleled with advances in adjunctive technology and pharmacological therapy to further improve outcome, but challenges remain for PPCI practitioners. The evidence behind PPCI is reviewed at every stage of the patient's journey.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2014) studied Myocardial ischemia-reperfusion (I/R) injury (n=48). EIP-22 vs. Scramble peptide (Scr) 10 mg/kg was evaluated on Myocardial infarction area and cardiac function (p=<.05). EIP-22 ameliorated myocardial ischemia-reperfusion injury, reduced apoptosis, and improved cardiac function in mice by activating the JAK2/STAT3 signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: